Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments,
In the merger, each share of AveXis common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Merger Sub, AveXis
Daiichi Sankyo oncology research and development global head and executive vice president Dr Antoine Yver said: “With a successful track record and our first bispecific antibody incorporating the
Indivior PLC and its U.S. subsidiary, Indivior Inc., marketers and distributors of SUBOXONE, joined partner Aquestive in the settlement with Par Pharmaceuticals, Inc., an operating company of Endo
Under the development agreement, Hemogenyx will receive on a cost-free basis technical support, access to advanced methods of discovering, developing and engineering antibodies, and certain intellectual property which
RXi Pharmaceuticals president and CEO Geert Cauwenbergh said: "Iovance is the leading company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. Our agreement will allow Iovance
Amryt estimates there may be up to 450 additional patients who could benefit from treatment with Lojuxta across the countries covered by the extended agreement, representing an increase
The committee’s non-binding recommendation will be considered by the FDA in its review of Akcea’s New Drug Application for WAYLIVRA. The PDUFA date for completion of the review
As per terms of the deal, Genentech will use Lodo Therapeutics’ genome mining and biosynthetic cluster assembly platform to discover novel molecules with therapeutic potential against multiple disease-related targets.
Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs), Escient will initially pursue therapies for neuro-immuno-inflammatory and autoreactive
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.